- Home
- IBRX vs CMPO Comparison
IBRX vs CMPO Comparison
Compare IBRX & CMPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- CMPO
- Stock Information
- Founded
- IBRX 2014
- CMPO 2000
- Country
- IBRX United States
- CMPO United States
- Employees
- IBRX N/A
- CMPO N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- CMPO Finance: Consumer Services
- Sector
- IBRX Health Care
- CMPO Finance
- Exchange
- IBRX Nasdaq
- CMPO Nasdaq
- Market Cap
- IBRX 2.3B
- CMPO 2.1B
- IPO Year
- IBRX N/A
- CMPO N/A
- Fundamental
- Price
- IBRX $2.53
- CMPO $20.18
- Analyst Decision
- IBRX Strong Buy
- CMPO Strong Buy
- Analyst Count
- IBRX 6
- CMPO 6
- Target Price
- IBRX $9.83
- CMPO $17.67
- AVG Volume (30 Days)
- IBRX 10.3M
- CMPO 1.0M
- Earning Date
- IBRX 11-11-2025
- CMPO 11-07-2025
- Dividend Yield
- IBRX N/A
- CMPO N/A
- EPS Growth
- IBRX N/A
- CMPO N/A
- EPS
- IBRX N/A
- CMPO N/A
- Revenue
- IBRX $56,600,000.00
- CMPO $267,817,999.00
- Revenue This Year
- IBRX $629.94
- CMPO $10.30
- Revenue Next Year
- IBRX $109.91
- CMPO $8.12
- P/E Ratio
- IBRX N/A
- CMPO N/A
- Revenue Growth
- IBRX 4227.22
- CMPO N/A
- 52 Week Low
- IBRX $1.83
- CMPO $9.24
- 52 Week High
- IBRX $7.48
- CMPO $21.00
- Technical
- Relative Strength Index (RSI)
- IBRX 47.77
- CMPO 56.24
- Support Level
- IBRX $2.42
- CMPO $19.71
- Resistance Level
- IBRX $2.75
- CMPO $20.87
- Average True Range (ATR)
- IBRX 0.13
- CMPO 0.68
- MACD
- IBRX -0.01
- CMPO -0.15
- Stochastic Oscillator
- IBRX 22.88
- CMPO 37.86
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.